Jun 11, 2026

Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics:

• Introduction: Which Biomarkers and When (0:00)
• Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31)
• SERENA-6 Trial (19:44)
• Inavolisib (23:08)

Jun 9, 2026

Featuring perspectives from Dr Christine L Hann and Dr Jacob Sands, including the following topics:

• Introduction: Biopharmacology of Small Cell Lung Cancer — “Wildfire sparked in dry grass” (0:00)
• Limited-Stage Disease (9:22)
• Extensive-Stage Disease (16:23)
• Paraneoplastic Syndromes — Lambert-Eaton Myasthenic...

Jun 9, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 1: Limited-Stage Small Cell Lung Cancer (SCLC); First-Line and Maintenance Therapy for Extensive-Stage SCLC — Jacob Sands, MD

CME information and select...

Jun 8, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 2: Management of Relapsed/Refractory SCLC; Promising Investigational Agents and Strategies — Christine L Hann, MD, PhD 

CME information and select...

Jun 5, 2026

Featuring perspectives from Prof Thomas Powles, including the following topics:

• Circulating tumor DNA (ctDNA) analyses with adjuvant nivolumab for MIBC in the CheckMate 274 study (0:00)
• Use of ctDNA to guide response-adapted bladder preservation for patients with MIBC (2:27)
• ctDNA response-adapted treatment...